Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-x(L) protein levels

Cell Death and Differentiation

Volumn 7, Issue 6, 2000, Pages 574-586

  Tudor, G ^a   Aguilera, A ^a   Halverson, D O ^a   Laing, N D ^a   Sausville, E A ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Bad; Bcl 2; Bcl 2 cleavage; Bcl x(L); Taxol (paclitaxel); Thiotepa

Indexed keywords

CASPASE 3; CYTOCHROME C; ENZYME PRECURSOR; PACLITAXEL; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL X; THIOTEPA;

APOPTOSIS; ARTICLE; CELL STRAIN HL 60; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0034064991     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4400688     Document Type: Article

References (59)

1. Reed JC (1997) Double identity for proteins of the Bcl-2 family. Nature 387: 773-776
2. Hockenberry D, Nunez G, Milliman C, Schreiber RD and Korsmeyer SJ (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336
3. Boise LH, Gonzales-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G and Thompson CB (1993) Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608
4. Krajewski S, Tanaka S, Takayama S, SchiblerMJ, Fenton W and Reed JC (1993) Investigations of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res. 53: 4701 -4714
5. Sato T, Hanada M, Bodrug S, Irie S, Iwama N, Boise LH, Thompson CB, Golemis E, Fong L, Wang HG and Reed JC (1994) Interactions among members of the bcl-2 protein family analyzed with a yeast two-hybrid system. Proc. Natl. Acad. Sci. USA 91: 9238-9242
6. Gonzalez-Garcia M, Perez-Ballestero R, Ding L, Duan L, Boise LH, Thompson CB and Nunez G (1994) Bcl-xL is the major Bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. Development 120: 3033-3042
7. Zhan Q, Alamo I, Yu K, Boise LH, Cherney B, Tosato G, O'Connor PM and Fornace AJ, Jr (1996) The apoptosis-associated gamma-ray response of Bcl-xL depends on normal p53 function. Oncogene 13: 2287-2293
8. Shimizu S, Eguchi Y, Kamiike W, Waguri S, Uchiyama Y, Matsuda H and Tsujimoto Y (1996) Bcl-2 blocks loss of mitochondrial membrane potential while ICE inhibitors act at a different step during inhibition of death induced by respiratory chain inhibitors. Oncogene 13:21-29
9. Kim CN, Wang X, Huang Y, Ibrado AM, Liu L, Fang G and Bhalla K (1997) Overexpression of Bcl-xL inhibits ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Cancer Res. 57: 3115-3120
10. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP and Wang X (1997) Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 257: 1129-1132
11. Yang E, Zha J, Jockel J, Boise LH, Thompson CB and Korsmeyer SJ(1995) Bad, a heterodirneric partner for Bcl-xL and Bcl-2, displaces Bax and promotes cell death. Cell 80: 285-291
12. Kelekar A, Chang BS, Harlan JE, Fesik SW and Thompson CB (1997) Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-xL. Mol. Cell Biol. 17: 7040-7046
13. Zha J, Harada H, Yang E, Jockel J and Korsmeyer J (1996) Serine phosphorylation of death agonist Bad in response to survival factor results in binding to 14.3.3 not Bcl-xL. Cell 87: 619-628
14. Datta SR, Dudek H, Tao X, Masters S, Fu HA, Gotoh Y and Greenberg ME (1997) Akt phosphorylation of Bad couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241
15. Chittenden T, Harrington EA, O'Connor R, Flemington C, Lutz RJ, Evan GI and Guild BC (1995) Induction of apoptosis by the Bcl-2 homologue Bak. Nature 374: 733-736
16. Oltvai ZN, Milliman CL and Korsmeyer S (1993) Bcl-2 heterodimerizes in-vivo with a conserved homologue, Bax, that accelerates programmed cell death. Cell 74:609-619
17. Manon S, Chaudhuri B and Guerin M (1997) Release of cytochrome c and decrease of cytochrome c oxidase in Bax-expressing yeast cells, and prevention of these effects by coexpression of Bcl-xL. FEBS Lett. 415: 29-32
18. Rosse T, Olivier R, Monney L, Rager M, Conus S, Fellay I, Jansen B and Borner C (1998) Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature 391: 496-499
19. Sedlak TW, Oltvai ZN, Yang E, Wang K, Boise LH, Thompson CB and Korsmeyer SJ (1995) Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc. Natl. Acad. Sci. USA 92: 7834-7838
20. Oltvai ZN and Korsmeyer SJ (1994) Checkpoint of dueling dimers foil death wishes. Cell 79: 189-192
21. Haldar S, Chintapalli J and Croce CM (1996) Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56: 1253-1255
22. Ito T, Deng XM, Carr B and May WS (1997) Bcl-2 phosphorylation required for anti-apoptosis function. J. Biol. Chem. 272: 11671-11673
23. May WS, Tyler PG, Ito T, Armstrong DK, Qatsha KA and Davidson NE (1994) lnterleukin-3 and bryostatin-1 mediate hyper-phosphorylation of Bcl-2 in association with suppression of apoptosis. J. Biol. Chem. 269: 26865-26870
24. Haldar S, Jena N and Croce CM (1995) Inactivation of Bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA 92: 4507-4511
25. Scatena CD, Stewart ZA, Mays D, Tang LJ, Keefer CJ, Leach SD and Pietenpol JA (1998) Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J. Biol. Chem. 273: 30777-30784
26. Ling YH, Tornos C and Perez-Soler R (1998) Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J. Biol. Chem. 273: 18984-18991
27. Cheng EHY, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K and Hardwich JM (1997) Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 278: 1966-1968
28. Thornberry NA and Lazebnik Y (1998) Caspases: enemies within. Science 281: 1312-1316
29. Martin SJ and Green DR (1995) Protease activation during apoptosis: death by a thousand cuts? Cell 82: 349-352
30. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X (1997) Cytochrome c and dATP-dependent formation of Apaf-1/Caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479-489
31. Cohen NA, Egorin MJ, Snyder SW, Ashar B, Wietharn BE, Pan S, Ross D and Hilton J (1991) Interaction of N,N′,N″-triethylenethiophosphoramide and N,N′,N″-triethylenephosphoramide with cellular DNA. Cancer Res. 51: 4360-4366
32. Musser SM, Pan SS, Egorin MJ, Kyle DJ and Callery PS (1992) Alkylation of DNA with aziridine produced during hydrolysis of N,N′,N″-triethylenethiophosphoramide. Chem. Res. Toxicol. 5: 95-99
33. Schiff PB, Fant J and Horwiz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667
34. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J and Mitchell JB (1993) Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br. J. Cancer 68: 1104-1109
35. Lopez NM, Adams EG, Pitts TW and Bhuyan KB (1993) Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol. 32: 235-242
36. Woods CM, Zhu J, McQueney PA, Bollag D and Lazarides E (1995) Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Molecular Medicine 1: 506-526
37. Wahl AF, Donaldson KL, Fairchild C, Lee FYF, Foster SA, Demers GW and Galloway DA (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med. 2: 72-79
38. Barboule N, Chadebech P, Baldin V, Vidal S and Valette A (1997) Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line. Oncogene 15: 2867-2875
39. Lee LF, Li G, Templeton DJ and Ting JP (1998) Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal Kinase (JNK/SAPK). J. Biol. Chem. 273: 28253-28260
40. Lieu CH, Liu CC, Yu TH, Chen KD, Chang YN and Lai YK (1998) Role of mitogen-activated protein kinase in taxol-induced apoptosis in human leukemic U937 cells. Cell Growth Differ. 9: 767-775
41. Blagosklonny MV, Schulte T, Nguyen P, Trepel J and Neckers LM (1996) Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res. 56: 1851-1854
42. Moos PJ and Fitzpatrick FA (1998) Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc. Natl. Acad. Sci. USA 95: 3896-3901
43. Ling YH, Consoli U, Tornos C, Andreeff M and Perez-Soler R (1998) Accumulation of Cyclin B1, activation of Cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with Taxol. Int. J. Cancer 75: 925-932
44. Amato SF, Swart JM, Berg M, Wanebo HJ, Mehta SR and Chiles TC (1998) Transient stimulation of the c-Jun-NH2-terminal kinase/activator protein 1 pathway and inhibition of extracellular signal-regulated kinase are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts. Cancer Res. 58: 241-247
45. Zha J, Harada H, Osipov K, Jockel J, Waksman G and Korsmeyer SJ (1997) BH3 domain of Bad is required for heterodimerization with Bcl-xL and pro-apoptotic activity. J. Biol. Chem. 272: 24101-24104
46. Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, Hoffman B and Liebermann D (1994) Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene 9: 1791-1798
47. Zhan Q, Fan S, Bae I, Guillouf C, Liebermann DA, O'Connor PM and Fornace AJ Jr (1994) Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 9: 3743-3751
48. Miyashita T and Reed TC (1995)Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299
49. Wang Q, Maloof P, Wang H, Fenig E, Stein D, Nichols G, Denny TN, Yahalom J and Wieder R (1998) Basic fibroblast growth factor downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells. Experimental Cell Research 238: 177-187
50. Mandal M and Kumar R (1996) Bcl-2 expression regulates sodium butyrate-induced apoptosis in human MCF-7 breast cancer cells. Cell Growth Differ. 7: 311-318
51. Simonian PL, Grillot DA and Nunez G (1997) Bak can accelerate chemotherapy-induced cell death independently of its heterodimerization with Bcl-xL and Bcl-2. Oncogene 15: 1871-1875
52. Simonian PL, Grillot DA, Merino R and Nunez G (1996) Bax can antagonize Bcl-xL during etoposide and cisplatin-induced cell death independently of its heterodimerization with Bcl-xL. J. Biol. Chem. 271: 22764-22772
53. Zha H and Reed JC (1997) Heterodimerization-independent functions of cell death regulatory proteins Bax and Bcl-2 in yeast and mammalian cells. J. Biol. Chem. 272: 31482-31488
54. Liu X, Kim CN, Yang J, Jemmerson R and Wang X (1996) Induction of the apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86: 147-157
55. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S and Reed JC (1998) Regulation of cell death protease Caspase-9 by phosphorylation. Science 282: 1318-1321
56. Bossy-Wetzel E, Newmeyer DD and Green DR (1998) Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J. 17: 37-49
57. Kitada S, Krajewska M, Zhang X, Scudiero D, Zapata JM, Wang HG, Shabaik A, Tudor G, Krajewski S, Myers TG, Johnson GS, Sausville EA and Reed JC (1998) Expression and localization of pro-apoptotic Bcl-2 family protein Bad in normal human tissues and tumor cell lines. Am. J. Path. 152: 51-61
58. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace Jr A and Kohn KW (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57: 4285-4300
59. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J and Boyd M (1991 ) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 83: 757-766